StoxZydus Lifesciences vs Cipla: share price & financials comparison
NSE: ZYDUSLIFE vs CIPLA · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Zydus Lifesciences vs Cipla at a glance
Zydus Lifesciences (ZYDUSLIFE) has a market capitalisation of ₹1,19,550 Cr, against ₹1,13,988 Cr for Cipla (CIPLA). Over the past year Zydus Lifesciences has returned +19.4%, compared with -10.8% for Cipla. On valuation, Zydus Lifesciences trades at a lower P/E of 28.6 versus 39.3. Zydus Lifesciences earns a higher return on equity (15.0% vs 8.2%). Zydus Lifesciences comes out ahead on size, profitability, growth, momentum and technicals. Cipla comes out ahead on valuation and financial health. Across the scored metrics below, Zydus Lifesciences leads on 14 and Cipla on 4. On StoxGud's 10-point checklist, Zydus Lifesciences scores 10/10 and Cipla scores 6/10.
| Metric | Zydus Lifesciences | Cipla |
|---|---|---|
| Size | ||
| Market cap | ₹1,19,550 Cr | ₹1,13,988 Cr |
| Revenue (latest FY) | ₹27,148 Cr | ₹28,163 Cr |
| Net profit (latest FY) | ₹5,040 Cr | ₹3,879 Cr |
| Valuation | ||
| P/E | 28.6 | 39.3 |
| P/B | 4.30 | 3.22 |
| Dividend yield | 0.93% | 1.13% |
| Profitability | ||
| Return on equity | 15.0% | 8.2% |
| Net profit margin | 13.8% | 10.3% |
| Operating margin | 27.0% | 17.0% |
| Growth | ||
| Revenue growth (YoY) | +29.2% | -2.4% |
| Net profit growth (YoY) | -26.5% | -35.1% |
| Revenue CAGR (multi-year) | +12.4% | +8.0% |
| Financial health | ||
| Debt to equity | 0.48 | 0.01 |
| Momentum | ||
| 1-month return | +3.9% | +6.3% |
| 1-year return | +19.4% | -10.8% |
| 3-year CAGR | +27.0% | +5.4% |
| 5-year CAGR | +19.4% | +9.1% |
| 10-year CAGR | +12.1% | +10.0% |
| Distance from 52W high | -3.8% | -8.4% |
| Technicals | ||
| RSI (14) | 67 | 82 |
| Price vs 200-day avg | +15.1% | +3.5% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Zydus Lifesciences | Cipla |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✗ |
| Positive 1-year return | ✓ | ✗ |
| Return on equity above 15% | ✓ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✗ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✓ | ✓ |
| Score | 10/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Zydus Lifesciences or Cipla?
Zydus Lifesciences has a market cap of ₹1,19,550 Cr and Cipla has a market cap of ₹1,13,988 Cr as of 06 Nov 2026.
Which has a lower P/E, Zydus Lifesciences or Cipla?
Zydus Lifesciences has the lower P/E: Zydus Lifesciences trades at 28.6 and Cipla at 39.3.
Which gave better returns in the last year, Zydus Lifesciences or Cipla?
Zydus Lifesciences did better: Zydus Lifesciences returned +19.4% and Cipla returned -10.8% over one year.
Is Zydus Lifesciences or Cipla a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Zydus Lifesciences scores 10/10 and Cipla scores 6/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.